BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sichuan Huiyu Pharmaceutical Co.\, Ltd readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Sichuan Huiyu Pharmaceutical Co.\
 , Ltd's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06712680-2763@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20280410
DTEND;VALUE=DATE:20280411
SUMMARY:HYP-6589: Phase 1/2 readout est. (NCT06712680)
DESCRIPTION:HYP-6589\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Ph
 ase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors a
 nd in Combination With Tyrosine Kinase Inhibitors in Treating Patients Wit
 h Advanced NSCLC Positive for Driver Genes\nEstimated primary completion: 
 10 April 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hyp-65
 89#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6712680
URL:https://assetmemo.bio/drug/hyp-6589#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
